Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | LOX | P28300 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393942 | 1.00 | CA1 (0.54) | CA1CA2CA4CA6PLCG1 | |
| SCHEMBL25350141 | 0.78 | LMNA (0.51) | CA1CA2CA4CA6PLCG1 | |
| SCHEMBL27688842 | 0.75 | MET (0.47) | CA1CA2HTR6CYP3A4 | |
| SCHEMBL6024620 | 0.75 | RAPGEF4 (0.53) | CA1CA2EPHX2EDNRAL3MBTL1 | |
| SCHEMBL8935031 | 0.75 | GAA (0.56) | CA1CA2CA4CA6HTR6 | |
| SCHEMBL38660050 | 0.72 | CA1 (0.68) | CA1CA2CA4CA6PLCG1 | |
| SCHEMBL2475835 | 0.72 | CA1 (0.68) | CA1CA2CA4CA6PLCG1 | |
| SCHEMBL29973515 | 0.72 | TSHR (0.66) | CA1CA2CA4CA6MAPT | |
| SCHEMBL15917236 | 0.72 | TSHR (0.71) | CA1CA2CA4CA6MAPT | |
| SCHEMBL29391601 | 0.72 | GAA (0.54) | CA1CA2CA4CA6PLCG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257373-A1 | QUORUM SENSING INHIBITORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH | 2023-08-17 | — | — | US | claimed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230257373-A1 | QUORUM SENSING INHIBITORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH | 2023-08-17 | — | — | US | disclosed |
| US-20230257373-A1 | QUORUM SENSING INHIBITORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH | 2023-08-17 | — | — | US | disclosed |
| US-20230257373-A1 | QUORUM SENSING INHIBITORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH | 2023-08-17 | — | — | US | disclosed |
| CN-115551862-A | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2022036282-A1 | QUORUM SENSING INHIBITORS AND METHODS OF USE | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2022-02-17 | — | — | WO | disclosed |
| CN-112125901-A | Inhibitors of lysine-specific demethylase-1 | 赛尔基因昆蒂赛尔研究公司 | 2020-12-25 | — | — | CN | disclosed |
| CN-107074787-B | Inhibitors of lysine-specific demethylase-1 | 赛尔基因昆蒂赛尔研究公司 | 2020-10-27 | — | — | CN | disclosed |
| EP-2951170-A2 | FLAP MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014121055-A2 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-07 | — | — | WO | disclosed |
| US-6673824-B1 | HYPOTENSIVE AGENTS | BRISTOL-MYERS SQUIBB CO. | 2004-01-06 | — | — | US | disclosed |
| CN-1066441-C | Phenyl sulfonamide endothelin antagonists | SQUIBB & SONS INC (US) | 2001-05-30 | — | — | CN | disclosed |
| US-6107320-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0569193-B1 | N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists | SQUIBB & SONS INC (US) | 1997-02-26 | — | — | EP | disclosed |
| US-5514696-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1996-05-07 | — | — | US | disclosed |
| CN-1084515-A | Phenyl sulfamoyl endothelium (endothelin) antagonistic | SQUIBB & SONS INC (US) | 1994-03-30 | — | — | CN | disclosed |
| EP-0569193-A1 | N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257373-A1 | QUORUM SENSING INHIBITORS AND METHODS OF USE | PGLS, BLVRB, CGAS | CA1 1251/4885CA2 134/4885CA4 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.